- Sean Cassidy leaving Arvinas as of February 29, 2024 - - Randy Teel, Ph.D. to assume the role of interim Chief Financial Officer -NEW HAVEN, Conn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a
Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced that the first patient has been dosed in its Phase 1b/2 clinical trial
U.S. stocks traded mixed, with the Nasdaq Composite gaining around 100 points on Friday.
Shares of SPS Commerce, Inc. (NASDAQ: SPSC) rose sharply during Friday’s session following upbeat results.